Immix Biopharma, Inc. (IMMX)
12.72
+0.80
(+6.71%)
USD |
NASDAQ |
Sep 17, 16:00
12.79
+0.07
(+0.55%)
Pre-Market: 09:17
Immix Biopharma Enterprise Value : 678.83M for Sept. 17, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 17, 2026 | 678.83M |
| September 16, 2026 | 621.60M |
| September 15, 2026 | 637.34M |
| September 14, 2026 | 642.35M |
| September 11, 2026 | 637.34M |
| September 10, 2026 | 677.40M |
| September 09, 2026 | 649.50M |
| September 08, 2026 | 716.74M |
| September 04, 2026 | 763.96M |
| September 03, 2026 | 758.23M |
| September 02, 2026 | 767.53M |
| September 01, 2026 | 771.11M |
| August 31, 2026 | 772.54M |
| August 28, 2026 | 766.10M |
| August 27, 2026 | 792.57M |
| August 26, 2026 | 775.40M |
| August 25, 2026 | 804.02M |
| August 24, 2026 | 742.50M |
| August 21, 2026 | 746.07M |
| August 20, 2026 | 710.30M |
| August 19, 2026 | 712.45M |
| August 18, 2026 | 613.73M |
| August 17, 2026 | 580.11M |
| August 14, 2026 | 553.64M |
| August 13, 2026 | 550.06M |
| Date | Value |
|---|---|
| August 12, 2026 | 582.26M |
| August 11, 2026 | 590.84M |
| August 10, 2026 | 493.55M |
| August 07, 2026 | 464.22M |
| August 06, 2026 | 488.54M |
| August 05, 2026 | 451.35M |
| August 04, 2026 | 436.32M |
| August 03, 2026 | 371.23M |
| July 31, 2026 | 364.07M |
| July 30, 2026 | 380.52M |
| July 29, 2026 | 353.34M |
| July 28, 2026 | 372.66M |
| July 27, 2026 | 390.54M |
| July 24, 2026 | 378.38M |
| July 23, 2026 | 398.41M |
| July 22, 2026 | 442.05M |
| July 21, 2026 | 453.49M |
| July 20, 2026 | 398.41M |
| July 17, 2026 | 502.14M |
| July 16, 2026 | 488.54M |
| July 15, 2026 | 522.17M |
| July 14, 2026 | 532.90M |
| July 13, 2026 | 521.45M |
| July 10, 2026 | 563.66M |
| July 09, 2026 | 562.23M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Atossa Therapeutics, Inc. | -2.254M |
| ACADIA Pharmaceuticals, Inc. | 3.842B |
| Alnylam Pharmaceuticals, Inc. | 32.51B |
| Anika Therapeutics, Inc. | 268.28M |
| Savara, Inc. | 970.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.56M |
| Total Expenses (Quarterly) | 11.56M |
| EPS Diluted (Quarterly) | -0.1812 |
| Earnings Yield | -6.92% |
| Normalized Earnings Yield | -6.920 |